Overview

Erlotinib for Treatment of Psoriasis

Status:
Withdrawn
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine whether erlotinib is effective in the treatment of psoriasis.
Phase:
Phase 2
Details
Lead Sponsor:
Northwestern University
Collaborator:
OSI Pharmaceuticals
Treatments:
Erlotinib Hydrochloride